Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial.

Shoichi MaruyamaShimon KurasawaTerumasa HayashiMasaomi NangakuIchiei NaritaHideki HirakataKenichiro TanabeSatoshi MoritaYoshiharu TsubakiharaEnyu ImaiTadao Akizawanull null

Published in: Clinical and experimental nephrology (2023)

Clinicaltrials.gov (identifier: NCT01581073).

Keyphrases

chronic kidney disease
end stage renal disease
type diabetes
glycemic control
cardiovascular disease
study protocol
phase iii
clinical trial
replacement therapy
red blood cell
adipose tissue
insulin resistance
skeletal muscle